News
LXRX
0.7849
+5.88%
0.0436
H.C. Wainwright Keeps Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
TipRanks · 2d ago
Weekly Report: what happened at LXRX last week (0203-0207)?
Weekly Report · 6d ago
Weekly Report: what happened at LXRX last week (0127-0131)?
Weekly Report · 02/03 09:22
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Exact Sciences (EXAS) and Amgen (AMGN)
TipRanks · 01/30 11:50
Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
TipRanks · 01/30 08:36
Lexicon Pharmaceuticals jumps amid takeover speculation
Seeking Alpha · 01/29 19:16
Lexicon rumor highlighted in Betaville alert
TipRanks · 01/29 19:15
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Benzinga · 01/29 12:00
Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold
Benzinga · 01/29 11:35
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
TipRanks · 01/29 11:17
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)
TipRanks · 01/27 17:30
Weekly Report: what happened at LXRX last week (0120-0124)?
Weekly Report · 01/27 09:22
Weekly Report: what happened at LXRX last week (0113-0117)?
Weekly Report · 01/20 09:21
Weekly Report: what happened at LXRX last week (0106-0110)?
Weekly Report · 01/13 09:22
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss
Simply Wall St · 01/07 12:28
Weekly Report: what happened at LXRX last week (1230-0103)?
Weekly Report · 01/06 09:23
Executive reshuffles: WELL, SLG and LXRX
Seeking Alpha · 01/04 20:54
Lexicon Pharmaceuticals Appoints New CFO Scott M. Coiante
TipRanks · 01/02 21:30
Lexicon Pharmaceuticals Names Scott Coiante Finance Chief
Dow Jones · 01/02 13:12
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Dow Jones · 01/02 13:00
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.